baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Inventiva SA/ FR0013233012 /

2024-05-28 5:35:25 PM	Chg. +0.005	Volume	Bid3:01:14 AM	Ask3:01:14 AM	High	Low
3.190EUR	+0.16%	15,243 Turnover: 48,649.740	3.170Bid Size: 300	3.190Ask Size: 249	3.230	3.160

GlobeNewswire 05-22 Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

GlobeNewswire 05-21 Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

GlobeNewswire 05-16 Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical t...

GlobeNewswire 05-13 Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase...

GlobeNewswire 04-03 Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on For...

GlobeNewswire 03-28 Inventiva announces the nomination of Andre Turenne as Director

GlobeNewswire 03-27 Inventiva reports its 2023 full-year results

GlobeNewswire 03-22 Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Res...

GlobeNewswire 03-18 Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lan...

GlobeNewswire 03-18 PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landma...

GlobeNewswire 03-13 Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagli...

GlobeNewswire 03-07 Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor ...

GlobeNewswire 02-15 Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its ...

GlobeNewswire 01-24 Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

GlobeNewswire 01-10 Inventiva draws down the second tranche of €25 million under existing Finance Contract with the Euro...

GlobeNewswire 2023-12-04 Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial wit...

GlobeNewswire 2023-11-21 Inventiva reports 2023 Third Quarter Financial Information¹

GlobeNewswire 2023-11-06 Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanif...

GlobeNewswire 2023-10-09 ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...

GlobeNewswire 2023-09-28 Inventiva reports its 2023 first-half financial results and provides a corporate update

GlobeNewswire 2023-09-20 Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercial...

GlobeNewswire 2023-08-31 Inventiva announces a financing of approximately €35.7 million from new and existing investors, cons...

GlobeNewswire 2022-03-08 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor a...

GlobeNewswire 2022-03-07 Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and ...

GlobeNewswire 2022-03-07 Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et ce...

Inventiva SA/ FR0013233012 /

If you wish to receive reply to your feedback, please provide your email address.